Abstract:For decades, the success of allogeneic hematopoietic stem cell transplant has highlighted the role of T cells in eliminating hematological tumors. This proof of concept pioneered the practice of the ex vivo generation and adoptive transfer of tumor-specific T cells (ATC), which became an effective modality, for example, for virus-associated diseases, like Epstein-Barr-virus-associated post-transplant lymphoproliferative disorders ( 1 ). A remarkable advance to the ATC field was pioneered by Eshhar and colleagues in 1993, when, rather than replicating the T-cell receptor (TCR)-mediated recognition of tumor molecules, which requires antigen processing and presentation through major histocompatibility complex (MHC) molecules, they generated chimeric antigen receptors (CAR) that target unprocessed antigens expressed on the cell surface of tumor cells in an MHC unrestricted fashion ( 2 ). Providing T cells with the ability to engage targets via an antibody-derived single-chain-variable-fragment (scFv) linked to the intracellular T-cell signaling domains was game changing because it overcomes HLA barriers and opens a whole new antigen repertoire for tumor recognition. While the first clinical application of CAR-T cells was for treatment of patients with HIV ( 3 ), this approach gained the most traction in hematological malignancies and was driven by the availability of lineage restricted antigens homogeneously expressed by hematological tumors. Specifically, targeting B-cell malignancies offered a much-needed route to success ( 4 – 6 ). The CD19 antigen promptly took the spotlight as meeting the fundamental requirements for ideal CAR targeting, namely: its high expression on tumor cells, expression at all stages of B-cell development and thus on derived tumors, and absent expression on vital tissues, with the potential for B-cell aplasia considered a risk-benefit ratio worth taking ( 7 ). The other major advantage provided by hematological malignancies is their accessibility. CAR-T cells infused intravenously are much more likely to interact with tumor cells that are circulating in the blood or located in the bone marrow and lymph nodes (or lymphatic system), compared with the those that require penetrating through a solid tumor stroma. Moving this technology to cancer treatment also required several advances in the laboratory. First, genetic modification of human cells became more mainstream, thanks to the development of efficient viral vectors, like lenti- and retro-virus based vectors, combined with the development of better protocols for vector production, cell transduction, and newer technologies for their safety monitoring ( 3 , 8 ). Second, recognizing the need for a costimulatory signal (known as signal 2) to promote full T-cell activation was key. The provision of just the CD3ζ or CD3γ endodomains that trigger the proximal signaling of the TCR to the first-generation CAR was in fact unable to replicate the physiological sequence of activation events that occur upon TCR engagement and proved to be sub-optimal in supporting CAR-T cell expansion and persistence ( 9 ). In contrast, including the intracellular domains of molecules such as CD28 or 4-1BB in tandem with the CAR supported the transmission of signals capable of producing the required sustained activation, proliferation, and effector function ( 10 – 12 ).

Generating CAR T cells from tumor-infiltrating lymphocytes

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

The Second Generation of Human Ipsc-Derived CAR-Macrophages for Immune Cell Therapies in Liquid and Solid Tumors

The Generation of CAR-Transfected Natural Killer T Cells for the Immunotherapy of Melanoma

Driving CAR T cells towards dermatologic oncology

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

CAR T cells for hematological malignancies

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment

Abstract 5342: Evaluation of autologous and allogeneic T cell-based therapies in ex-vivo and in-vivo xenograft tumor models

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Abstract 2835: Chimeric antigen receptor (CAR) T-cell generation for therapeutic testing in the disseminated NALM6 human B-cell acute lymphoblastic leukemia mouse model

Development of CAR T cells designed to improve antitumor efficacy and safety

Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Coengineering specificity, safety, and function into T cells for cancer immunotherapy

Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy

CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation

CAR T-cell immunotherapy: The path from the by-road to the freeway?